Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Plus Therapeutics (NASDAQ:PSTV) but lowers the price target from $21 to $20.

September 03, 2024 | 9:34 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Plus Therapeutics but lowers the price target from $21 to $20.
The analyst's decision to maintain a Buy rating suggests continued confidence in the stock's potential, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100